(Q53179735)

12 May 2018

title

Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. (English)

1 reference

12 May 2018

0 references

1 reference

1 reference

1 reference

Powell RJ

1

1 reference

12 May 2018

Frew AJ

series ordinal

2

1 reference

12 May 2018

Corrigan CJ

series ordinal

3

1 reference

12 May 2018

Durham SR

series ordinal

4

1 reference

12 May 2018

publication date

21 August 2007

1 reference

12 May 2018

published in

Allergy

1 reference

12 May 2018

volume

62

1 reference

12 May 2018

issue

11

1 reference

12 May 2018

page(s)

1335-1338

1 reference

12 May 2018

National prevalence of respiratory allergic disorders

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2007.01455.X

10.1111/J.1398-9995.2007.01455.X

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018